Atossa Therapeutics Newsroom

H.C. Wainwright Maintains Atossa Therapeutics(ATOS.US) With Buy Rating, Maintains Target Price $7

Moomoo NewsDec 12 12:31 ET · Ratings

Express News | HC Wainwright & Co. Reiterates Buy on Atossa Therapeuticsto Buy

BenzingaDec 12 12:25 ET

Atossa Therapeutics Analyst Ratings

BenzingaDec 12 12:24 ET · Ratings

Express News | Atossa Therapeutics To Present Data Describing the Discovery of Compounds That May Be Synergistic With (Z)-Endoxifen And That Could Potentially Be Used in Combinations For The Treatment Of Breast Cancer. The Data Will Be Presented In A Poster At The...

BenzingaDec 12 08:20 ET

Atossa Therapeutics to Present Poster Describing the Discovery of Molecules Synergistic With (Z)-endoxifen for the Treatment of Breast Cancer at the 2024 San Antonio Breast Cancer Symposium

Atossa TherapeuticsDec 12 00:00 ET

Atossa Therapeutics Announces Full Result From KARISMA-Endoxifen Trial

TipRanksDec 11 08:20 ET

Atossa Therapeutics Announces Resuts From Phase 2 KARISMA-Endoxifen Study

TipRanksDec 11 08:20 ET

Atossa Therapeutics Announces Full Results From Phase 2 KARISMA-Endoxifen Study To Be Presented At 2024 San Antonio Breast Cancer Symposium; Demonstrated Statistically Significant Reductions In Mammographic Breast Density

BenzingaDec 11 08:17 ET

Express News | Atossa Therapeutics: 2 Mg Dose Was Associated With Higher Rates of Hot Flashes, Night Sweats and Vaginal Discharge

ReutersDec 11 08:16 ET

Express News | Atossa Therapeutics - 1 Mg Dose Reduced Mbd by 17.3 Percentage Points, 2 Mg Dose by 23.5 Vs Minimal Change in Placebo Group of 0.27

ReutersDec 11 08:15 ET

Express News | Atossa Therapeutics Inc - 1 Mg Dose (Z)-Endoxifen Shows Potential as Preventative Breast Cancer Therapy

ReutersDec 11 08:15 ET

Express News | Atossa Therapeutics Announces Full Results From Phase 2 Karisma-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density

ReutersDec 11 08:15 ET

Atossa Therapeutics Announces Full Results From Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density

Atossa TherapeuticsDec 11 00:00 ET

Atossa Therapeutics to Present Pharmacokinetic and Tolerability Data From Phase 2 EVANGELINE Trial at the 2024 San Antonio Breast Cancer Symposium

GlobeNewswireDec 10 09:05 ET

Atossa Therapeutics Is Maintained at Buy by Ascendiant Capital

Dow JonesDec 9 05:02 ET · Ratings

Atossa Therapeutics to Present Poster on (Z)-Endoxifen at AACR Special Conference in Cancer Research

Atossa TherapeuticsNov 21 00:00 ET

Atossa Therapeutics Announces Five Abstracts on Z-endoxifen

TipRanksNov 20 08:41 ET

Express News | Atossa Therapeutics To Present Five Abstracts For Data Regarding (Z)-Endoxifen At 2024 San Antonio Breast Cancer Symposium

BenzingaNov 20 08:31 ET

Express News | Atossa Therapeutics- Got Into Open Market Sale Agreement, May Offer & Sell Shares of Our Common Stock of up to $100 Mln From Time to Time - SEC Filing

ReutersNov 19 16:32 ET

H.C. Wainwright Maintains Atossa Therapeutics(ATOS.US) With Buy Rating, Raises Target Price to $7

Moomoo NewsNov 13 06:31 ET · Ratings